Evidence map›Paper›PMID 37154023›Full record

ArticleMolecular and cellular biology2023

EPRS1 Controls the TGF-

Ina Yoon, Ji Ae Song, Ji Hun Suh, Sulhee Kim, Jonghyeon Son, Jong Hyun Kim, Song Yee Jang, Kwang Yeon Hwang, Myung Hee Kim, Sunghoon Kim

Open access · hybridAbstract read
In one paragraph

Article in Molecular and cellular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ina YoonInstitute for Artificial Intelligence and Biomedical Research, Medicinal Bioconvergence Research Center, Yonsei University, Incheon, Republic of Korea.
Ji Ae SongInstitute for Artificial Intelligence and Biomedical Research, Medicinal Bioconvergence Research Center, Yonsei University, Incheon, Republic of Korea.
Ji Hun SuhInstitute for Artificial Intelligence and Biomedical Research, Medicinal Bioconvergence Research Center, Yonsei University, Incheon, Republic of Korea.
Sulhee KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Jonghyeon SonNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Republic of Korea.
Jong Hyun KimDepartment of Biochemistry, School of Medicine, Catholic University of Daegu, Daegu, Republic of Korea.
Song Yee JangMicrobiome Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea Research Republic of Korea.
Kwang Yeon HwangDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Myung Hee KimMicrobiome Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea Research Republic of Korea.
Sunghoon KimInstitute for Artificial Intelligence and Biomedical Research, Medicinal Bioconvergence Research Center, Yonsei University, Incheon, Republic of Korea.ORCID 0000-0002-1570-3230
Yonsei University · KRDaegu Catholic University · KRKorea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutamyl-prolyl-tRNA synthetase 1 (EPRS1) is known to associated with fibrosis through its catalytic activity to produce prolyl-tRNA. Although its catalytic inhibitor halofuginone (HF) has been known to inhibit the TGF-β pathway as well as to reduce prolyl-tRNA production for the control of fibrosis, the underlying mechanism how EPRS1 regulates the TGF-β pathway was not fully understood. Here, we show a noncatalytic function of EPRS1 in controlling the TGF-β pathway and hepatic stellate cell activation via its interaction with TGF-β receptor I (TβRI). Upon stimulation with TGF-β, EPRS1 is phosphorylated by TGF-β-activated kinase 1 (TAK1), leading to its dissociation from the multi-tRNA synthetase complex and subsequent binding with TβRI. This interaction increases the association of TβRI with SMAD2/3 while decreases that of TβRI with SMAD7. Accordingly, EPRS1 stabilizes TβRI by preventing the ubiquitin-mediated degradation of TβRI. HF disrupts the interaction between EPRS1 and TβRI, and reduces TβRI protein levels, leading to inhibition of the TGF-β pathway. In conclusion, this work suggests the novel function of EPRS1 involved in the development of fibrosis by regulating the TGF-β pathway and the antifibrotic effects of HF by controlling both of EPRS1 functions.

Indexed as

Hepatic Stellate CellsReceptors, Transforming Growth Factor betaFibrosisHumansReceptor, Transforming Growth Factor-beta Type ISignal TransductionTransforming Growth Factor betaReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type ITransforming Growth Factor betaglutamyl-prolyl-tRNA synthetase 1halofuginonetransforming growth factor receptors

Identifiers

PMID37154023
PMCPMC10184599
OpenAlexW4375955140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.